

CORE DIAGNOSTICS

Sigma Metrics for Next Generation Clinical Chemistry Assays

Authors: M. Berman, S. Gawel, V. Petrides



Table of Contents

1 BACKGROUND	3
2 METHODS	3
3 SIGMA DATA	4
4 CONCLUSION	6

1. Background

Six Sigma is a well-established tool that can objectively assess the performance of a process with the goal of increasing quality output and minimizing error. Although these metrics began in the manufacturing sector, Six Sigma has been applied across numerous industries, including healthcare. For laboratorians, Six Sigma (or Sigma) metrics are useful for assessing the performance of instruments and assays. An optimal process will have a Sigma value of 6 (6-Sigma) or greater, which indicates a defect rate of 3.4 errors per million opportunities. Healthcare processes in general, and laboratory test performance specifically, can fall short of this metric. The Sigma values for laboratory processes are typically in the 3 to 4 range and sometimes even lower¹. For comparison, a Sigma value of 3 (3-Sigma) indicates a defect rate of 66,800 errors per million, which is considered marginal performance and not ideal from a clinical perspective.


Sigma metrics are also valuable for benchmarking and comparing different laboratory assays or comparator systems; this is an especially helpful tool when a side by side comparison would be expensive due to the large number of products offered per system. A Sigma metric compares the precision and bias performance of the assay to the laboratory total allowable error (TEa) goal. Achieving a Sigma value of 6 is a mark of world-class assay performance. Unfortunately, most clinical chemistry and immunoassays on the market do not meet this standard².



Assays with high Sigma values benefit the laboratory by reducing errors and providing clinicians with consistent and accurate results. This 'right first-time' paradigm improves turn-around-time (TAT), curtailing the need for repeat testing³. Turn-around-time is an essential benchmark for labs to leverage patient and clinician satisfaction, and it also influences patient care⁴. Hospital performance indicators, such as Emergency Department (ED) length of stay, are influenced by lab TAT⁵. Thus, high-performing assays (high Sigma) can add value to patient care and provide better customer satisfaction than average-performing assays.

These benefits allow a lab to remain competitive, reduce headcount needs, and decrease quality control testing to remain financially solvent in today's evolving healthcare marketplace.

Figure 1: Sigma Metric Variables



2. Methods

This study evaluated the Sigma performance of 8 ARCHITECT and 6 Alinity c system clinical chemistry assays across several therapeutic areas. A Sigma metric was calculated for each assay per the following equation:

$$\text{SIGMA METRIC} = (\text{TEa} - |\text{BIAS}|) / \text{PRECISION}$$

THE SIGMA METRIC VARIABLES ARE:

TEa:

The assay-specific total allowable error (TEa) was obtained from recognized organizations such as Clinical Laboratory Improvement Amendments (CLIA) and German Medical Association on Quality Assurance in Medical Laboratory Examinations – Rili-BAEK.

Bias:

Bias is the difference between the measured value and the true value of a sample. For calculating bias, the use of an internationally recognized standard or method is preferred to allow comparison across different manufacturer systems. A recognized standard or reference method (e.g., NIST) at a medically relevant concentration was tested. The % difference from the target was calculated as the bias.

Precision:

The precision of an assay describes the variability of the measurement of a sample and is often reported as a coefficient of variation (CV). In this study, the within-laboratory CV was used from a sample with a concentration near to that of the reference sample used to determine the bias.

After calculating Sigma metrics for each assay, a precision profile chart was created to compare the precision performance of the assays tested on the ARCHITECT and Alinity c systems.

3. Sigma Data

Low imprecision and bias were observed across the measuring intervals for all of the next generation ARCHITECT and Alinity c system clinical chemistry assays tested (Table 1a and 1b). Additionally, 6-Sigma metrics were achieved for 6 of the ARCHITECT clinical chemistry assays tested and all of the Alinity c clinical chemistry assays tested (Figure 2a and 2b). Furthermore, the data highlight the accuracy of these assays when measured against recognized standards, even when tested at a low medically relevant concentration for each analyte across both platforms.

Table 1a: Sigma Metrics for Next Generation ARCHITECT Clinical Chemistry Assays

ARCHITECT Assays	Standard	Target	%CV	% Bias	TE _a	Sigma
Cholesterol ₂	Reference Method Abell-Kendall	236 mg/dL	2.0	1.1	10 ^a	4.3
Creatinine ₂	NIST SRM 967a	0.85 mg/dL	3.5	-0.8	20 ^c	5.4
Urea Nitrogen ₂	NIST SRM 912	70 mg/dL	1.7	1.7	15.7 ^b	7.9
Albumin BCG ₂	ERM-DA470	3.7 g/dL	1.6	1.3	14 ^c	8.1
Amylase ₂	IRMM/ IFCC 456	309 U/L	1.6	0.5	15.7 ^b	9.3
Albumin BCP ₂	ERM-DA470	3.7 g/dL	1.4	-0.4	14 ^c	9.8
Uric Acid ₂	NIST SRM 913c	10 mg/dL	1.2	-0.3	13 ^d	10.8
Total Protein ₂	NIST SRM 927	7.0 g/dL	0.8	-0.5	10 ^d	11.3

a. CLIA proficiency testing criteria for acceptable analytical performance, as printed in the Federal Register February 28, 1992;57(40):7002-7186.

b. Ricós C, Alvarez V, Cava F, et al. Current databases on biological variation: pros, cons and progress. *Scand J Clin Lab Invest.* 1999;59(7):491-500

c. Minimum analytical performance specifications of inter-laboratory comparisons: agreement among Spanish EQAP organizers (2012) DOI 10.1515/CCLM.2011.787 Clin Chem Lab Med, Volume 50 (3), Pages 455-461 C. Ricós, F. Ramón, Á. Salas, A. Buno, R. Calafell, J. Moranco, G. Gutiérrez-Bassini, J.M. Jou.

d. De Gruyter. Revision of the "Guideline of the German Medical Association on Quality Assurance in Medical Laboratory Examinations – Rili-BAEK" DOI 10.1515/labmed-2014-0046 *J Lab Med.* 2015, 39(1): 26-69.

Figure 2a: Sigma Metrics for Next Generation ARCHITECT Clinical Chemistry Assays




Table 1b: Sigma Metrics for Next Generation Alinity c Clinical Chemistry Assays

Alinity c Assays	Standard	Target	%CV	% Bias	TE _a	Sigma
Albumin BCG2	ERM-DA470	3.7 g/dL	1.4	4.8	14 ^c	6.6
Total Protein ₂	NIST SRM 927	7.0 g/dL	1.2	-1.6	10 ^d	7.2
Albumin BCP2	ERM-DA470	3.7 g/dL	1.3	-1.9	14 ^c	9.5
Uric Acid ₂	NIST SRM 913c	7 mg/dL	1.0	2.5	13 ^d	10.5
Cholesterol ₂	Reference Method Abell-Kendall	212 mg/dL	0.7	0.6	10 ^a	13.4
Amylase ₂	IRMM/ IFCC 456	309 U/L	1.0	1.7	15.7 ^b	13.5


a. CLIA proficiency testing criteria for acceptable analytical performance, as printed in the Federal Register February 28, 1992;57(40):7002-7186.

b. Ricós C, Alvarez V, Cava F, et al. Current databases on biological variation: pros, cons and progress. *Scand J Clin Lab Invest.* 1999;59(7):491-500

c. Minimum analytical performance specifications of inter-laboratory comparisons: agreement among Spanish EQAP organizers (2012) DOI 10.1515/CCLM.2011.787 Clin Chem Lab Med, Volume 50 (3), Pages 455-461 C. Ricós, F. Ramón, Á. Salas, A. Buno, R. Calafell, J. Morancho, G. Gutiérrez-Bassini, J.M. Jou.


d. De Gruyter. Revision of the "Guideline of the German Medical Association on Quality Assurance in Medical Laboratory Examinations – Rili-BAEK" DOI 10.1515/labmed-2014-0046 *J Lab Med.* 2015, 39(1): 26-69.

Figure 2b: Sigma Metrics for Next Generation Alinity c Clinical Chemistry Assays



The Sigma profile chart in Figure 3 shows the consistency in assay quality results across the ARCHITECT and Alinity c platforms. With most assays performing in the 6-Sigma range, laboratory personnel can have confidence in the results reported for these clinical chemistry assays on the ARCHITECT and Alinity c platforms.

Figure 3: Normalized Method Decision Chart



4. Conclusion

In today's healthcare environment, a laboratory's measure of success and profitability is increasingly driven by the satisfaction of its customers: physicians, nurses, patients, and laboratory personnel. Selecting assays that offer higher efficacy and reliability can give a lab confidence in their results and provide a competitive advantage. Sigma metrics are a powerful tool for selecting the most sensitive assays and allowing for comparison of assay performance across platforms and vendors. Sigma metrics of 6 or higher signify world-class assay performance, a key objective for Abbott during the assay design process. The exceptional performance of the ARCHITECT and Alinity c

next generation clinical chemistry assays tested in this study reflect this commitment to world-class assay design and performance.

Transitioning to assays that achieve a high Sigma metric can aid laboratorians in meeting that 'right first-time' performance target, which leads to improved turnaround time (TAT). When both accuracy and TAT excel, lab personnel can be confident in the performance of their assays, offering tremendous value to the healthcare system and positively influencing patient care.

REFERENCES:

1. Nevalainen D, Berte L, Kraft C, Leigh E, Picaso L, Morgan T. Evaluating laboratory performance on quality indicators with the six sigma scale. *Arch Pathol Lab Med.* 2000;124(4):516-519.
2. Westgard S, Westgard QC. SIX SIGMA: Laboratory Quality Control in the Healthcare Ecosystem. Abbott Laboratories. 2020. Available at: https://www.corelaboratory.abbott/sal/whitePaper/ADD-00058828_SixSigma_Standards_of_Quality.pdf. Accessed July 20, 2021.
3. Abbott Laboratories. TOTAL VALUE OF OWNERSHIP: Is your laboratory demonstrating its true value? April 2018. Available at: <https://www.corelaboratory.abbott/sal/document/ADD-00063489%20Total%20Value%20of%20Ownership%20TVO%20Article.pdf>. Accessed July 20, 2021.
4. Hawkins RC. Laboratory turnaround time. *Clin Biochem Rev.* 2007;28(4):179-194.
5. Kaushik N, Khangulov VS, O'Hara M, Arnaout R. Reduction in laboratory turnaround time decreases emergency room length of stay. *Open Access Emerg Med.* 2018;10:37-45.

CORELABORATORY.ABBOTT

For *in vitro* diagnostic use only.

All ARCHITECT analyzers are Class 1 laser products.

© 2021 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. ADD-132705-GBL-EN (v1.0) 07/21

